Official websites use .gov
A
.gov
website belongs to an official government organization in the
United States.
Secure .gov websites use HTTPS
A
lock
(
) or
https://
means you’ve safely connected to the .gov website. Share sensitive
information only on official, secure websites.
PubMed ID:
31171572
Public Release Type:
Journal
Publication Year: 2019
DOI:
https://doi.org/10.1681/ASN.2018121227
Authors:
Hayek Salim S., Landsittel Douglas P., Wei Changli, Zeier Martin, Yu Alan S.L., Torres Vicente E., Roth Sharin, Pao Christina S., Reiser Jochen
Request IDs:
21643
Studies:
Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease
Soluble urokinase plasminogen activator receptor (suPAR), a marker of inflammation, is also an independent marker for incidence and progression of renal diseases. Mechanistically, it has been shown to activate podocytes in glomerular diseases. In this study, the authors provide the first description linking suPAR levels with disease progression for a major genetic renal disease that mainly affects the extraglomerular compartment, autosomal dominant polycystic kidney disease (ADPKD). They found an association between suPAR levels and height-adjusted total kidney volume, independent of age, sex, race, hypertension, and eGFR. In addition, patients with suPAR levels >2.82 ng/ml had a 3.38-fold increase in risk of incident ESRD. These findings suggest that suPAR levels may be useful for early identification of patients with ADPKD at high risk of disease progression.
